Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for Pulmonary Fibrosis in COVID-19
NCT04338802Phase 2Unknown
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of nintedanib in pulmonary fibrosis (PF). Status: unknown.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04338802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338802.